Pediatric AML demonstrated notable sensitivity to two small-molecule inhibitors, SB505124_1194 (a selective TGFβR inhibitor) and RAF265 CHIR.265 (a BRAF inhibitor). The gene discussed is BRAF; the disease is acute myeloid leukemia.